Proffitt & Goodson’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12K | Hold |
31
| – | – | ﹤0.01% | 233 |
|
|
2026
Q1 | $9.08K | Hold |
31
| – | – | ﹤0.01% | 229 |
|
|
2025
Q4 | $10.9K | Hold |
31
| – | – | ﹤0.01% | 223 |
|
|
2025
Q3 | $10K | Hold |
31
| – | – | ﹤0.01% | 255 |
|
|
2025
Q2 | $12.1K | Hold |
31
| – | – | ﹤0.01% | 204 |
|
|
2025
Q1 | $13.5K | Hold |
31
| – | – | ﹤0.01% | 196 |
|
|
2024
Q4 | $11.4K | Hold |
31
| – | – | ﹤0.01% | 193 |
|
|
2024
Q3 | $16.1K | Hold |
31
| – | – | ﹤0.01% | 201 |
|
|
2024
Q2 | $16.8K | Sell |
31
-10
| -24% | -$5.29K | ﹤0.01% | 202 |
|
|
2024
Q1 | $21.3K | Sell |
41
-5
| -11% | -$2.49K | ﹤0.01% | 182 |
|
|
2023
Q4 | $21.7K | Hold |
46
| – | – | ﹤0.01% | 172 |
|
|
2023
Q3 | $20K | Hold |
46
| – | – | ﹤0.01% | 177 |
|
|
2023
Q2 | $20.4K | Hold |
46
| – | – | ﹤0.01% | 173 |
|
|
2023
Q1 | $21.2K | Hold |
46
| – | – | ﹤0.01% | 175 |
|
|
2022
Q4 | $23.6K | Hold |
46
| – | – | 0.01% | 176 |
|
|
2022
Q3 | $21K | Hold |
46
| – | – | ﹤0.01% | 179 |
|
|
2022
Q2 | $22K | Sell |
46
-7
| -13% | -$3.46K | ﹤0.01% | 189 |
|
|
2022
Q1 | $26K | Hold |
53
| – | – | ﹤0.01% | 201 |
|
|
2021
Q4 | $25K | Sell |
53
-23
| -30% | -$9.68K | ﹤0.01% | 179 |
|
|
2021
Q3 | $28K | Hold |
76
| – | – | 0.01% | 176 |
|
|
2021
Q2 | $29K | Sell |
76
-20
| -21% | -$7.64K | 0.01% | 190 |
|
|
2021
Q1 | $34K | Sell |
96
-49
| -34% | -$15.8K | 0.01% | 177 |
|
|
2020
Q4 | $47K | Sell |
145
-10
| -6% | -$3.07K | 0.01% | 156 |
|
|
2020
Q3 | $42K | Sell |
155
-24
| -13% | -$6.46K | 0.01% | 150 |
|
|
2020
Q2 | $47K | Sell |
179
-157
| -47% | -$41.9K | 0.01% | 141 |
|
|
2020
Q1 | $76K | Sell |
336
-72
| -18% | -$19.6K | 0.02% | 100 |
|
|
2019
Q4 | $123K | Sell |
408
-243
| -37% | -$66.9K | 0.03% | 95 |
|
|
2019
Q3 | $156K | Sell |
651
-270
| -29% | -$74K | 0.04% | 91 |
|
|
2019
Q2 | $260K | Sell |
921
-4
| -0.4% | -$1.09K | 0.06% | 80 |
|
|
2019
Q1 | $265K | Sell |
925
-3,803
| -80% | -$1.1M | 0.07% | 75 |
|
|
2018
Q4 | $1.24M | Sell |
4,728
-11
| -0.2% | -$3.02K | 0.34% | 38 |
|
|
2018
Q3 | $1.3M | Sell |
4,739
-209
| -4% | -$54.3K | 0.33% | 32 |
|
|
2018
Q2 | $1.18M | Sell |
4,948
-605
| -11% | -$140K | 0.51% | 22 |
|
|
2018
Q1 | $1.22M | Sell |
5,553
-265
| -5% | -$62.3K | 0.52% | 24 |
|
|
2017
Q4 | $1.31M | Sell |
5,818
-683
| -11% | -$145K | 0.54% | 24 |
|
|
2017
Q3 | $1.23M | Sell |
6,501
-757
| -10% | -$144K | 0.54% | 25 |
|
|
2017
Q2 | $1.36M | Sell |
7,258
-2,161
| -23% | -$388K | 0.61% | 20 |
|
|
2017
Q1 | $1.56M | Sell |
9,419
-605
| -6% | -$96.2K | 0.73% | 18 |
|
|
2016
Q4 | $1.44M | Buy |
10,024
+70
| +0.7% | +$9.37K | 0.73% | 21 |
|
|
2016
Q3 | $1.25M | Buy |
9,954
+380
| +4% | +$49.1K | 0.65% | 29 |
|
|
2016
Q2 | $1.26M | Buy |
9,574
+22
| +0.2% | +$3.01K | 0.69% | 22 |
|
|
2016
Q1 | $1.33M | Buy |
9,552
+540
| +6% | +$72.2K | 0.76% | 17 |
|
|
2015
Q4 | $1.26M | Buy |
9,012
+360
| +4% | +$49.6K | 0.74% | 16 |
|
|
2015
Q3 | $1.21M | Sell |
8,652
-1,763
| -17% | -$265K | 0.76% | 20 |
|
|
2015
Q2 | $1.71M | Sell |
10,415
-655
| -6% | -$105K | 1% | 11 |
|
|
2015
Q1 | $1.71M | Sell |
11,070
-850
| -7% | -$121K | 1% | 11 |
|
|
2014
Q4 | $1.5M | Buy |
+11,920
| New | +$1.47M | 0.88% | 14 |
|
Other funds holding ELV
Proffitt & Goodson's ELV Position: Q2 2026 in Review
Proffitt & Goodson held its Elevance Health (ELV) position steady in Q2 2026 at 31 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #233.
Proffitt & Goodson first reported a position in ELV in Q4 2014 and has held it in 47 quarters since. The position peaked at $1.71M in Q2 2015. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Proffitt & Goodson held 31 shares of Elevance Health worth $12K as of Q2 2026.
- Proffitt & Goodson left its Elevance Health share count unchanged in Q2 2026.
- Elevance Health made up ﹤0.01% of Proffitt & Goodson's portfolio in Q2 2026, its #233 holding.
- Proffitt & Goodson first reported a position in Elevance Health in Q4 2014 and has held it in 47 quarters since.
- Proffitt & Goodson's Elevance Health position peaked at $1.71M in Q2 2015.
- 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Proffitt & Goodson's 13F filing for Q2 2026, filed 22 Jul 2026.